Previously Reported was Lexicon Pharmaceuticals’s largest revenue line in fiscal 2018, bringing in $25.21M of $25.37M (99%).
| Restatement | FY 2018 |
|---|---|
| Previously Reported | $25.21M |
| Adjustments | $167.00K |
| Total | $25.37M |
Lexicon Pharmaceuticals brought in $25.37M from its two revenue lines in fiscal 2018, the year ended March 31, 2018. Previously Reported was the largest at $25.21M (99.3%), ahead of Adjustments at $167.00K (0.7%).
Lexicon Pharmaceuticals (LXRX) reports its revenue by restatement. In fiscal 2018, Previously Reported was its largest revenue line, bringing in $25.21M (99.3% of the total), followed by Adjustments at $167.00K (0.7%).
Previously Reported was Lexicon Pharmaceuticals' largest revenue line in fiscal 2018, bringing in $25.21M, or 99.3% of the $25.37M total across its two revenue lines.
Every figure comes from Lexicon Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Lexicon Pharmaceuticals gives it, and years follow its fiscal calendar.
Lexicon Pharmaceuticals' revenue by restatement goes back to fiscal 2018, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.